



INSTITUTIONAL BIOSAFETY COMMITTEE

Wednesday, October 15th, 2025

9:00 AM

Location: UWPD Conference Room and Zoom

Members Present: Yun Li, Holly Steinkraus, Grant Bowman (Chair), Chelsea Mitchell, Michelle Nunnaley, and Hannah Goodnight

Members Absent: David Perry (Co-Chair)

Others Present: Chad Bade (UW Safety Office), Jim Herrold (UW Safety Office) Kevin Macartney (UW Safety Office), Vitoria Mattos- Pereira (REDD) and Jenna Martin (General Counsel)

Open Meeting: The public may attend the meeting by request.

Quorum: There was a quorum present. A simple majority of members is required for a quorum.

Call to Order: At 9:01 AM Grant Bowman called to order the meeting of the UW Institutional Biosafety Committee (IBC). Hannah Goodnight took minutes.

Approval of Minutes: Steinkraus moved to accept the minutes. Mitchell seconded the motion. The motion passed unanimously.

Protocol Review:

1. Dr. Izabela Ragan: "Owl Herpes Virus diagnostic development"-BAT

Ragan was present for overview of project. PI provided information that supports the species specificity of the owl virus and also explained that passage of viruses in vero cells is a common and low-risk procedure. Spoke in depth about the Vero cell line. After further conversation, the virus is species-specific and the PI stated that Vero Cell lines are a universal cell line for propagating viruses. If the virus does not propagate, then she will move onto chicken cell lines. Chair was ok with this after further discussion. The committee had minor comments to the project.

Motion by Steinkraus to approve protocol pending minor revisions and to be reviewed by Bowman and Goodnight. Seconded by Li. The motion passes unanimously.

2. Dr. Izabela Ragan: "Vaccines for Malignant Catarrhal Fever in Bison"- BAT

Ragan was present for an overview of the project and comments. Continuation from a previous PI in Vet Sci Department who has left the institution. Goodnight asked questions about containment. PI stated that this virus is fatal to the Bison and Cattle industry and made it a ABSL-2Ag.

Dr. Ragan Left Meeting.

Motion by Li to approve protocol pending lifetime of virus after shedding and facility structural considerations. Seconded by Steinkraus. The motion passes unanimously.

3. Dr. Sarah Kane: "Monitoring the fate of amyloid-prone proteins in response to pathogenic insults"- BAT

Kane was present. Kane went over the overview of project. We discussed the expectations with immunocompromised individuals. Discussed bacterial growth and incubations, and detailing strains in the protocol submission. Requested making specific mentions of the passage of the viral agents in registration.

Dr. Kane Left Meeting.

Motion by Steinkraus to approve minor revisions by Bowman and Goodnight. Seconded by Li. The motion passes unanimously.

4. Dr. Florence Teulé-Finley: "Bacterial production of recombinant spider silk proteins and characterization"- rDNA
5. Dr. Florence Teulé-Finley: "The Effects of Citrullination on Tubulin Function"- rDNA

Teulé-Finley was not present. Bowman gave overview of both the protocols. No comments on project.

Motion by Steinkraus to approve both protocols as written. Seconded by Mitchell. The motion passes unanimously.

Old Business

Procedure for submitting IBC and changes to workflow: Still working on this and will be able to provide updates and documentation next meeting, so it can be implemented in January/February 2026.

Suyama Project: Bowman asked for an update. Goodnight informed committee that the lab passed inspection as a BSL-2 lab. PI needs to send follow up comments.

DURC Srednik. Goodnight will follow up with email.

New Business

Biosafety Cabinet Update: UWSO (Biosafety Specialist) is working on the contract for TSS. All BSCs that are in protocol submissions that are "expired" are on the list to get certified AS SOON AS the Contract is processed through.

Sent out information for the NIH's "[Modernizing and Strengthening Oversight of Biosafety](#)". *NIH is launching a new Biosafety Modernization Initiative to strengthen biosafety policies, practices, and oversight to keep pace with the evolving risks posed by today's rapidly advancing science and technology. As part of this initiative, NIH will modernize our existing biosafety policy to holistically address the emergent biosafety needs of today.* Please take a look at this when you can, to be informed. UW falls under region 5. When region 5 posts a listening session, Goodnight will send out to the IBC members.

Next Meeting

The next meeting of the IBC will be on Wednesday, November 19th, 2025, at 9 AM in the UWPD conference room.

Adjournment

Steinkraus moved to adjourn the meeting, Li seconded the motion. The motion passed unanimously. The meeting adjourned at 10:18 AM.

Minutes submitted by Goodnight.